CANbridge Life Sciences Submits Investigational New Drug Application for CAN017 Trial in Esophageal Squamous Cell Cancer (ESCC) in China
Dec 21, 2017
CANbridge Completes Patient Enrolment for Phase I Clinical Trial of CAN008 in Treatment of Glioblastoma Multiforme in Taiwan
Nov 30, 2017
CAN008 Injection for the Treatment of Gbm China Taiwan Phase I Data Releasing
Nov 02, 2017
James Xue is Appointed to Leadership and Development Council Member
Sep 26, 2017
CANbridge Life Sciences Appoints Chief Business Officer Will Head First US Office
Sep 12, 2017
CANbridge Congratulates Apogenix APG101 Receiving Ema “Prime” Designation
Jul 26, 2017
CANbridge Submits Ind Application for CAN008 PHII/III Trial in GBM in China
Jul 18, 2017
James Xue, Founder and CEO of CANbridge, Present at 2017 China GCP Conference
Jun 08, 2017
James Xue, Founder and CEO of CANbridge, Present at 2017 Boston CEO Conference
Jun 01, 2017